# A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

> **NCT03691649** · PHASE3 · COMPLETED · sponsor: **Santen Inc.** · enrollment: 426 (actual)

## Conditions studied

- Glaucoma and Ocular Hypertension

## Interventions

- **DRUG:** DE-117 Ophthalmic Solution
- **DRUG:** Timolol Maleate Ophthalmic Solution 0.5%

## Key facts

- **NCT ID:** NCT03691649
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2019-12-06
- **Final completion:** 2020-09-03
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691649, "A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03691649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*